Bayer joined hands with Heart Association HCM City to improve community’s heart health
Ho Chi Minh City, Vietnam. March 15-16, 2014 – Bayer Healthcare Pharmaceuticals in cooperation with Heart Association HCM City hosted an educational symposium for medical experts to share knowledge and best practices as well as to facilitate the discussion of current challenges, strategies and advancements in cardiovascular healthcare throughout the world.
“Cardiovascular disease is the leading cause of mortality worldwide, ahead of infectious diseases, and its prevalence is projected to increase due to rapidly evolving environments and population demographics. It is therefore important that we reinforce current prevention and interventional strategies addressing the risk factors of cardiovascular disease, and continue with our therapeutic advancements towards managing this global burden,” said the Chair of the Heart Health Symposium 2014, Dang Van Phuoc, MD, PhD, Professor of University of Medicine and Pharmacy at HCM City, President of Heart Association HCM City.
The symposium brought together more than 350 medical experts i.e. cardiologists, neurologists and general practitioners from countries all over the Asia Pacific region including Vietnam. Six major topics were addressed in the two-day symposium i.e. (1) The importance of Heart Health, with the emphasis on the impact of multiple cardiovascular risk factors, (2) The Evolution of Cardiovascular Disease Prophylaxis, (3) Reaching Blood Pressure Goals in guidelines of European Society of Cardiology/European Society of Hypertension, (4) Metabolic Risk Factors and Cardiovascular Disease, (5) Challenges of Anticoagulation, (6) Pulmonary Hypertension: The challenges to the healthcare professionals due to its complexity.
Heart Health Symposium 2014 to share knowledge and best practices as well as to facilitate the discussion of current challenges, strategies and advancements in cardiovascular healthcare throughout the world
Among them, the topic Challenges of Anticoagulation raised the most interest. Stroke prevention in non-valvular Atrial Fibrillation (AF) patients has been included in the clinical practice guidelines with novel anticoagulants therapies. AF is currently still a concern for the high risk of stroke. According to statistics data (Wolf et al. 1991, Marini et al 2005, Kannel et al. 2008, Miyasaka et al 2006), AF induced strokes generally results in the following severe consequences: 50% of AF induced strokes lead to death while the remaining 50% results in permanent disability.
Heart Health Symposium 2014 is a scientific activity among many others which showcase Bayer’s commitment in supporting healthcare professionals in cardiovascular healthcare management. The symposium gathered leading experts to share knowledge and therapeutic strategies, thereby contributing to an improvement in the community’s heart health in countries all over the region as well as in Vietnam.
About Bayer HealthCare
The Bayer Group is a global enterprise with core competencies in the fields of health care, agriculture and high-tech materials. Bayer HealthCare, a subgroup of Bayer AG with annual sales of EUR 18.9 billion (2013), is one of the world’s leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions. Bayer HealthCare’s aim is to discover, develop, manufacture and market products that will improve human and animal health worldwide. Bayer HealthCare has a global workforce of 56,000 employees (Dec 31, 2013) and is represented in more than 100 countries.
More information at www.healthcare.bayer.com.